Risk of fatigue and anemia in patients with advanced cancer treated with olaparib: a meta-analysis of randomized controlled trials

Measuring inconsistency in meta-analyses

Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139 · see citing works

Bias in meta-analysis detected by a simple, graphical test

Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722 · see citing works

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.

(2009) · PubMed Central · Cited by 44,859 · see citing works

Meta-analysis in clinical trials

DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552 · see citing works

The Cochrane Collaboration's tool for assessing risk of bias in randomised trials

Higgins, J. P. T., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., Savovic, J., Schulz, K. F., Weeks, L., Sterne, J. A. C., et al. (2011) · BMJ · doi:10.1136/bmj.d5928 · Cited by 33,817 · see citing works

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.06.005 · Cited by 19,575 · see citing works

Assessing the quality of reports of randomized clinical trials: Is blinding necessary?

Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J. M., Gavaghan, D. J., & McQuay, H. J. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(95)00134-4 · Cited by 17,582 · see citing works

Operating characteristics of a rank correlation test for publication bias

Begg, C. B., & Mazumdar, M. (1994) · Biometrics · doi:10.2307/2533446 · Cited by 16,955 · see citing works

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683 · see citing works

Olaparib for Metastatic Breast Cancer in Patients with a Germline <i>BRCA</i> Mutation

Robson, M., Im, S.-A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., Delaloge, S., Li, W., Tung, N., Armstrong, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706450 · Cited by 3,294 · see citing works

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

Pujade-Lauraine, É., Ledermann, J. A., Selle, F., Gebski, V., Penson, R. T., Oza, A. M., Korach, J., Huzarski, T., Poveda, A. M., Pignata, S., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30469-2 · Cited by 1,856 · see citing works

Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial

Ledermann, J. A., Harter, P., Gourley, C., Friedlander, M. L., Vergote, I. B., Rustin, G. J. S., Scott, C. L., Meier, W., Shapira‐Frommer, R., Safra, T., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70228-1 · Cited by 1,437 · see citing works

Impact of Cancer-Related Fatigue on the Lives of Patients: New Findings From the Fatigue Coalition

Curt, G. A., Breitbart, W., Cella, D., Groopman, J. E., Horning, S. J., Itri, L. M., Johnson, D. H., Miaskowski, C., Scherr, S. L., Portenoy, R. K., et al. (2000) · The Oncologist · doi:10.1634/theoncologist.5-5-353 · Cited by 1,248 · see citing works

Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer

Konstantinopoulos, P. A., Ceccaldi, R., Shapiro, G. I., & D'Andrea, A. D. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0714 · Cited by 945 · see citing works

Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action

Pommier, Y. G., O’Connor, M. J., & Bono, J. S. D. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf9246 · Cited by 742 · see citing works

Mechanisms of Cancer-Related Fatigue

Ryan, J. L., Carroll, J. K., Ryan, E. P., Mustian, K. M., Fiscella, K. A., & Morrow, G. R. (2007) · The Oncologist · doi:10.1634/theoncologist.12-s1-22 · Cited by 588 · see citing works

Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial

Oza, A. M., Cibula, D., Benzaquen, A. O., Poole, C. J., Mathijssen, R. H. J., Sonke, G. S., Colombo, N., Špaček, J., Vuylsteke, P., Hirte, H. W., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71135-0 · Cited by 546 · see citing works

Assessment and management of cancer-related fatigue in adults

Ahlberg, K., Ekman, T., Gaston‐Johansson, F., & Mock, V. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14186-4 · Cited by 545 · see citing works

Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells

Patel, A. G., Sarkaria, J. N., & Kaufmann, S. H. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1013715108 · Cited by 543 · see citing works

FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy

Kim, G. S., Ison, G., McKee, A. E., Zhang, H., Tang, S.-H., Gwise, T., Sridhara, R., Lee, E. Y., Tzou, A., Philip, R., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0887 · Cited by 508 · see citing works

Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients With BRCA1 or BRCA2 Mutations and Recurrent Ovarian Cancer

Kaye, S. B., Lubiński, J., Matulonis, U. A., Ang, J. E., Gourley, C., Karlan, B. Y., Amit, A., Bell‐McGuinn, K. M., Chen, L.-M., Friedlander, M. L., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.9215 · Cited by 470 · see citing works

Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial

Clarke, N. W., Wiechno, P., Alekseev, B. Y., Sala, N., Jones, R., Kocák, I., Chiurì, V. E., Jassem, J., Fléchon, A., Redfern, C. H., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30365-6 · Cited by 397 · see citing works

Risk factors, prevalence, and course of severe fatigue after breast cancer treatment: a meta-analysis involving 12,327 breast cancer survivors

Abrahams, H. J. G., Gielissen, M. F. M., Schmits, I. C., Verhagen, C. A. H. H. V. M., Rovers, M. M., & Knoop, H. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw099 · Cited by 383 · see citing works

Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial.

Bang, Y., Xu, R.-H., Chin, K., Lee, K.-W., Park, S., Rha, S., Shen, L., Qin, S., Xu, N., Im, S., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30682-4 · Cited by 270 · see citing works

Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer.

Bang, Y., Im, S., Lee, K., Cho, J., Song, E., Lee, K., Kim, Y.-H., Park, J., Chun, H., Zang, D., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.0320 · Cited by 249 · see citing works

PARP inhibitor combination therapy

Dréan, A., Lord, C. J., & Ashworth, A. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.10.010 · Cited by 212 · see citing works

Safety and dose modification for patients receiving niraparib

Berek, J. S., Matulonis, U. A., Peen, U., Ghatage, P., Mahner, S., Redondo, A., Lesoin, A., Colombo, N., Vergote, I. B., Rosengarten, O. S., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy181 · Cited by 188 · see citing works

PARP1- and CTCF-Mediated Interactions between Active and Repressed Chromatin at the Lamina Promote Oscillating Transcription

Zhao, H., Sifakis, E. G., Sumida, N., Millán-Ariño, L., Scholz, B. A., Svensson, J. P., Chen, X., Ronnegren, A. L., de Lima, C. D. M., Varnoosfaderani, F. S., et al. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.07.019 · Cited by 138 · see citing works

Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial

Friedlander, M. L., Gebski, V., Gibbs, E., Davies, L. C., Bloomfield, R., Hilpert, F., Wenzel, L. B., Eek, D., Rodrigues, M. J., Clamp, A. R., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30343-7 · Cited by 135 · see citing works

Risk of severe hematologic toxicities in cancer patients treated with PARP inhibitors: a meta-analysis of randomized controlled trials

Zhou, J., Feng, L. J., & Zhang, X. (2017) · Drug Design Development and Therapy · doi:10.2147/dddt.s147726 · Cited by 103 · see citing works

Treatment-related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: An up-to-date review and meta-analysis of clinical trials

Santoni, M., Conti, A., Massari, F., Arnaldi, G., Iacovelli, R., Rizzo, M., Giorgi, U. D., Trementino, L., Procopio, G., Tortora, G., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.28715 · Cited by 53 · see citing works

The Era of PARP inhibitors in ovarian cancer: “Class Action” or not? A systematic review and meta-analysis

Staropoli, N., Ciliberto, D., Giudice, T. D., Iuliano, E., Cucè, M., Grillone, F., Salvino, A., Barbieri, V., Russo, A. D., Tassone, P., et al. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.08.011 · Cited by 40 · see citing works

Practical guidance on the use of olaparib capsules as maintenance therapy for women with BRCA mutations and platinum‐sensitive recurrent ovarian cancer

Friedlander, M. L., Banerjee, S. N., Mileshkin, L., Scott, C. L., Shannon, C., & Goh, J. C. H. (2016) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.12636 · Cited by 39 · see citing works

Fatigue, alopecia and stomatitis among patients with breast cancer receiving cyclin-dependent kinase 4 and 6 inhibitors: a systematic review and meta-analysis

Lasheen, S., Shohdy, K. S., Kassem, L. M. H., & Abdel-Rahman, O. M. (2017) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2017.1355242 · Cited by 35 · see citing works

Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A randomized phase 2 study (GOAL, Spanish Lung Cancer Group).

Campelo, R. G., Rodríguez, Ó. G. A., Massutí, B., Rodríguez‐Abreu, D., Granados, A. L. O., Majem, M., Vicente, D., LIANES, P., Bosch‐Barrera, J., Insa, A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.9012 · Cited by 13 · see citing works

Frequency, severity and timing of common adverse events (AEs) with maintenance olaparib in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC).

Matulonis, U. A., Friedlander, M. L., du Bois, A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.5550 · Cited by 12 · see citing works

Pilot randomized trial of an acceptance-based telehealth intervention for women with ovarian cancer and PARP inhibitor-related fatigue

Wright, A. A., Poort, H., Tavormina, A., Schmiege, S. J., Matulonis, U. A., Campos, S. M., Liu, J. F., Slivjak, E. T., Gilmour, A. L., Salinger, J. M., et al. (2023) · Gynecologic Oncology · doi:10.1016/j.ygyno.2023.08.020 · Cited by 11 · see citing works

Olaparib-Resistant BRCA2MUT Ovarian Cancer Cells with Restored BRCA2 Abrogate Olaparib-Induced DNA Damage and G2/M Arrest Controlled by the ATR/CHK1 Pathway for Survival

Biegała, Ł., Gajek, A., Marczak, A., & Rogalska, A. (2023) · Cells · doi:10.3390/cells12071038 · Cited by 28 · see citing works

Overexpressed ABCB1 Induces Olaparib-Taxane Cross-Resistance in Advanced Prostate Cancer

Lombard, A. P., Liu, C., Armstrong, C. M., D'Abronzo, L. S., Lou, W., Chen, H., Dall’Era, M., Ghosh, P., Evans, C. P., & Gao, A. C. (2019) · Translational Oncology · doi:10.1016/j.tranon.2019.04.007 · Cited by 32 · see citing works

PARP inhibitor olaparib sensitizes cholangiocarcinoma cells to radiation

Mao, Y., Huang, X., Shuang, Z., Lin, G., Wang, J., Duan, F., Chen, J., & Li, S. (2018) · Cancer Medicine · doi:10.1002/cam4.1318 · Cited by 48 · see citing works

Efficacy and mechanism of the combination of PARP and CDK4/6 inhibitors in the treatment of triple-negative breast cancer

Zhu, X.-Z., Chen, L., Huang, B., Li, X., Liu, Y., Hu, X., Jiang, Y., Shao, Z., & Wang, Z. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01930-w · Cited by 98 · see citing works

Downregulation of APE1 potentiates breast cancer cells to olaparib by inhibiting PARP-1 expression

Ma, X., Dang, C., Min, W., et al. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-019-05189-w · Cited by 22 · see citing works